NASDAQ:KNSA
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc's revenue grew 60.1% in fiscal 2025 to $677.6M while operating margin rose to 11.4%, its highest in 5 years. Free cash flow was $136.4M, 20.1% of revenue, and the diluted share count rose 10.6%.Summary generated from Kiniksa Pharmaceuticals International, plc's SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$677.6M
Revenue growth+60.1%
Revenue, 5-yr CAGRn/a
Gross margin88.5%
Operating margin11.4%
Net margin8.7%
ROICn/a
Return on equity11.7%
Debt / equityn/a
Free cash flow$136.4M
FCF margin20.1%
Share count change+10.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 39 | 220 | 270 | 423 | 678 |
| Operating income | −157 | 10 | −25 | −46 | 77 |
| Net income | −158 | 183 | 14 | −43 | 59 |
| Free cash flow | −127 | 6 | 13 | 25 | 136 |
Recent filings
- 4Insider transaction report
Sep 3, 2026 - 4Insider transaction report
Sep 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 28, 2026 - 8-KResults of operations and financial condition
Jul 28, 2026 - 8-KResults of a shareholder vote
May 29, 2026 - 8-KEntry into a material agreement
May 26, 2026 - 8-KDirector or officer change
May 1, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 28, 2026